<p>Insulet Corporation (NASDAQ:PODD - 获取免费报告) 的股价在周三的午盘交易中下跌了 3.4%，原因是高盛集团将该股票的目标价从 399.00 美元下调至 375.00 美元。高盛集团目前对该股票维持买入评级。Insulet 的最低交易价格为 305.22 美元，最后交易价格为 298.14 美元。在交易过程中，约有 50,130 股易手，较 742,312 股的日均交易量下降了 93%。该股票之前的收盘价为 308.73 美元。</p>
<ul>
<li>2025 年表现优异的 3 只医疗科技股票</li>
</ul>
<p>其他一些分析师最近也对该公司发布了报告。杰富瑞金融集团在 8 月 7 日的研究报告中重申了对 Insulet 股票的 “买入” 评级。摩根大通将 Insulet 的目标价从 340.00 美元上调至 415.00 美元，并在 9 月 12 日的研究报告中给予该股票 “超配” 评级。巴克莱将 Insulet 的目标价从 266.00 美元上调至 300.00 美元，并在 8 月 21 日的研究报告中给予该公司 “等权重” 评级。华尔街 Zen 在 8 月 9 日的报告中将 Insulet 的评级从 “持有” 上调至 “买入”。最后，奥本海默在 9 月 8 日的报告中将 Insulet 的目标价从 324.00 美元上调至 365.00 美元，并给予该股票 “跑赢大盘” 评级。十六位股票研究分析师对该股票给予了买入评级，另外两位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 345.47 美元。</p>
<p><strong>获取我们最新的 PODD 股票分析</strong></p>
<h2>Insulet 的内部买卖情况</h2>
<ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶级表现者</li>
</ul>
<p>在相关消息中，SVP Laetitia Cousin 在 9 月 8 日的交易中出售了 797 股 Insulet 股票。该股票以 348.81 美元的平均价格出售，总交易额为 278,001.57 美元。交易完成后，该高级副总裁直接持有该公司 3,890 股股票，价值 1,356,870.90 美元。此次交易使其持股减少了 17.00%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，SVP Prem Singh 在 9 月 8 日的交易中出售了 687 股 Insulet 股票。该股票以 347.49 美元的平均价格出售，总价值为 238,725.63 美元。出售后，该高级副总裁持有该公司 3,456 股股票，价值约为 1,200,925.44 美元。这代表其持股减少了 16.58%。该出售的披露信息可以在这里找到。内部人士持有该公司 0.39% 的股票。</p>
<h2>Insulet 的机构交易情况</h2>
<p>对冲基金最近买卖了该公司的股票。Inspire Investing LLC 在第一季度将其在 Insulet 的股份增加了 299.5%。Inspire Investing LLC 现在拥有 4,119 股医疗仪器供应商的股票，价值 1,082,000 美元，此前在该期间购买了 3,088 股。Allspring Global Investments Holdings LLC 在第一季度将其在 Insulet 的持股增加了 55.5%。Allspring Global Investments Holdings LLC 现在拥有 5,229 股医疗仪器供应商的股票，价值 1,376,000 美元，此前在上个季度增加了 1,867 股。高盛集团在第一季度将其在 Insulet 的持股增加了 1.9%。高盛集团现在拥有 579,302 股医疗仪器供应商的股票，价值 152,130,000 美元，此前在上个季度购买了 10,628 股。Gradient Investments LLC 在第二季度购买了 Insulet 的新股份，价值 17,429,000 美元。最后，Vident Advisory LLC 在第一季度获得了 Insulet 的新股份，价值 216,000 美元。</p>
<h2>Insulet 股票下跌 5.9%</h2>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p>该公司的市值为 204.5 亿美元，市盈率为 88.85，市盈增长比率为 2.58，贝塔值为 1.36。该公司的流动比率为 2.26，速动比率为 1.81，债务股本比率为 0.64。该公司的 50 日移动平均线为 320.07 美元，200 日移动平均线为 297.80 美元。</p>
<p>Insulet (NASDAQ:PODD - 获取免费报告) 最近在 8 月 7 日发布了季度财报。该医疗仪器供应商报告本季度每股收益为 1.17 美元，超出市场共识预期的 0.92 美元，超出幅度为 0.25 美元。Insulet 的股本回报率为 23.78%，净利润率为 10.01%。该公司本季度的收入为 6.491 亿美元，而分析师预期为 6.1231 亿美元。在去年同期，该公司每股收益为 0.55 美元。与去年同期相比，该公司的收入增长了 32.9%。Insulet 已将其 2025 财年的每股收益指引设定为每股收益。2025 年第三季度的指引为每股收益。平均而言，股票研究分析师预测 Insulet Corporation 本年度将发布 3.92 美元的每股收益。</p>
<h2>关于 Insulet</h2>
<p>(获取免费报告)</p>
<p>Insulet Corporation 开发、制造和销售用于胰岛素依赖型糖尿病患者的胰岛素输送系统。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统在 Pod 中嵌入了专有的 AID 算法，可以通过无线蓝牙通信与第三方连续血糖监测仪集成以获取血糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，配备彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴胰岛素输送系统，提供 72 小时的固定速率连续速效胰岛素。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Insulet</li>
<li>现在可以购买的三只沃伦·巴菲特股票</li>
<li>直觉外科是否是医疗行业疲软中的隐藏赢家？</li>
<li>投资者如何从盘后交易中获益</li>
<li>锂美洲股票上周暴涨——原因在这里</li>
<li>期权交易 - 理解行使价格</li>
<li>为什么亚马逊最新的升级可能是其最重要的一次</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Insulet 吗？</h2>
<p>在考虑 Insulet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Insulet 并不在名单上。</p>
<p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PODD

<p>Insulet Corporation（纳斯达克代码：PODD）在高盛将其目标股价从 399 美元下调至 375 美元的消息后，股价下跌了 3.4%，同时维持买入评级。该股最低交易价为 305.22 美元，收盘价为 298.14 美元，交易量较平均水平下降了 93%。尽管如此，其他分析师仍然给予了积极评级，普遍评级为 “适度买入”，目标价为 345.47 美元。Insulet 最近的财报显示出显著的收入增长，超出预期</p>

<p>Insulet Corporation (NASDAQ:PODD - Get Free Report)'s share price was down 3.4% during mid-day trading on Wednesday after The Goldman Sachs Group lowered their price target on the stock from $399.00 to $375.00. The Goldman Sachs Group currently has a buy rating on the stock. Insulet traded as low as $305.22 and last traded at $298.14. Approximately 50,130 shares changed hands during trading, a decline of 93% from the average daily volume of 742,312 shares. The stock had previously closed at $308.73.</p>
<div class="lb-trans"><p>Insulet Corporation (NASDAQ:PODD - 获取免费报告) 的股价在周三的午盘交易中下跌了 3.4%，原因是高盛集团将该股票的目标价从 399.00 美元下调至 375.00 美元。高盛集团目前对该股票维持买入评级。Insulet 的最低交易价格为 305.22 美元，最后交易价格为 298.14 美元。在交易过程中，约有 50,130 股易手，较 742,312 股的日均交易量下降了 93%。该股票之前的收盘价为 308.73 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优异的 3 只医疗科技股票</li>
</ul>
</div><p>A number of other analysts have also recently issued reports on the company. Jefferies Financial Group reissued a &#34;buy&#34; rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase &amp; Co. increased their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, September 12th. Barclays upped their price objective on Insulet from $266.00 to $300.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, August 21st. Wall Street Zen raised Insulet from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 9th. Finally, Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, September 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $345.47.</p>
<div class="lb-trans"><p>其他一些分析师最近也对该公司发布了报告。杰富瑞金融集团在 8 月 7 日的研究报告中重申了对 Insulet 股票的 “买入” 评级。摩根大通将 Insulet 的目标价从 340.00 美元上调至 415.00 美元，并在 9 月 12 日的研究报告中给予该股票 “超配” 评级。巴克莱将 Insulet 的目标价从 266.00 美元上调至 300.00 美元，并在 8 月 21 日的研究报告中给予该公司 “等权重” 评级。华尔街 Zen 在 8 月 9 日的报告中将 Insulet 的评级从 “持有” 上调至 “买入”。最后，奥本海默在 9 月 8 日的报告中将 Insulet 的目标价从 324.00 美元上调至 365.00 美元，并给予该股票 “跑赢大盘” 评级。十六位股票研究分析师对该股票给予了买入评级，另外两位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 345.47 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PODD</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PODD 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Insulet</h2>
<div class="lb-trans"><h2>Insulet 的内部买卖情况</h2>
</div><ul>
<li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li>
</ul>
<div class="lb-trans"><ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶级表现者</li>
</ul>
</div><p>In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，SVP Laetitia Cousin 在 9 月 8 日的交易中出售了 797 股 Insulet 股票。该股票以 348.81 美元的平均价格出售，总交易额为 278,001.57 美元。交易完成后，该高级副总裁直接持有该公司 3,890 股股票，价值 1,356,870.90 美元。此次交易使其持股减少了 17.00%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，SVP Prem Singh 在 9 月 8 日的交易中出售了 687 股 Insulet 股票。该股票以 347.49 美元的平均价格出售，总价值为 238,725.63 美元。出售后，该高级副总裁持有该公司 3,456 股股票，价值约为 1,200,925.44 美元。这代表其持股减少了 16.58%。该出售的披露信息可以在这里找到。内部人士持有该公司 0.39% 的股票。</p>
</div><h2>Institutional Trading of Insulet</h2>
<div class="lb-trans"><h2>Insulet 的机构交易情况</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Inspire Investing LLC lifted its stake in shares of Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after purchasing an additional 3,088 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after acquiring an additional 1,867 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock valued at $152,130,000 after purchasing an additional 10,628 shares during the last quarter. Gradient Investments LLC purchased a new stake in shares of Insulet during the 2nd quarter valued at $17,429,000. Finally, Vident Advisory LLC acquired a new stake in shares of Insulet during the 1st quarter worth $216,000.</p>
<div class="lb-trans"><p>对冲基金最近买卖了该公司的股票。Inspire Investing LLC 在第一季度将其在 Insulet 的股份增加了 299.5%。Inspire Investing LLC 现在拥有 4,119 股医疗仪器供应商的股票，价值 1,082,000 美元，此前在该期间购买了 3,088 股。Allspring Global Investments Holdings LLC 在第一季度将其在 Insulet 的持股增加了 55.5%。Allspring Global Investments Holdings LLC 现在拥有 5,229 股医疗仪器供应商的股票，价值 1,376,000 美元，此前在上个季度增加了 1,867 股。高盛集团在第一季度将其在 Insulet 的持股增加了 1.9%。高盛集团现在拥有 579,302 股医疗仪器供应商的股票，价值 152,130,000 美元，此前在上个季度购买了 10,628 股。Gradient Investments LLC 在第二季度购买了 Insulet 的新股份，价值 17,429,000 美元。最后，Vident Advisory LLC 在第一季度获得了 Insulet 的新股份，价值 216,000 美元。</p>
</div><h2>Insulet Stock Down 5.9%</h2>
<div class="lb-trans"><h2>Insulet 股票下跌 5.9%</h2>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p>The firm has a market capitalization of $20.45 billion, a PE ratio of 88.85, a price-to-earnings-growth ratio of 2.58 and a beta of 1.36. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average of $320.07 and a two-hundred day moving average of $297.80.</p>
<div class="lb-trans"><p>该公司的市值为 204.5 亿美元，市盈率为 88.85，市盈增长比率为 2.58，贝塔值为 1.36。该公司的流动比率为 2.26，速动比率为 1.81，债务股本比率为 0.64。该公司的 50 日移动平均线为 320.07 美元，200 日移动平均线为 297.80 美元。</p>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the previous year, the company posted $0.55 EPS. The company's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.</p>
<div class="lb-trans"><p>Insulet (NASDAQ:PODD - 获取免费报告) 最近在 8 月 7 日发布了季度财报。该医疗仪器供应商报告本季度每股收益为 1.17 美元，超出市场共识预期的 0.92 美元，超出幅度为 0.25 美元。Insulet 的股本回报率为 23.78%，净利润率为 10.01%。该公司本季度的收入为 6.491 亿美元，而分析师预期为 6.1231 亿美元。在去年同期，该公司每股收益为 0.55 美元。与去年同期相比，该公司的收入增长了 32.9%。Insulet 已将其 2025 财年的每股收益指引设定为每股收益。2025 年第三季度的指引为每股收益。平均而言，股票研究分析师预测 Insulet Corporation 本年度将发布 3.92 美元的每股收益。</p>
</div><h2>About Insulet</h2>
<div class="lb-trans"><h2>关于 Insulet</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p>
<div class="lb-trans"><p>Insulet Corporation 开发、制造和销售用于胰岛素依赖型糖尿病患者的胰岛素输送系统。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统在 Pod 中嵌入了专有的 AID 算法，可以通过无线蓝牙通信与第三方连续血糖监测仪集成以获取血糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，配备彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴胰岛素输送系统，提供 72 小时的固定速率连续速效胰岛素。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Insulet</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness?</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>Lithium Americas Stock Exploded Last Week—Here’s Why</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Why Amazon’s Latest Upgrade Might Be Its Most Important Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Insulet</li>
<li>现在可以购买的三只沃伦·巴菲特股票</li>
<li>直觉外科是否是医疗行业疲软中的隐藏赢家？</li>
<li>投资者如何从盘后交易中获益</li>
<li>锂美洲股票上周暴涨——原因在这里</li>
<li>期权交易 - 理解行使价格</li>
<li>为什么亚马逊最新的升级可能是其最重要的一次</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insulet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insulet 吗？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insulet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Insulet 并不在名单上。</p>
</div><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insulet（NASDAQ:PODD）股价在分析师下调评级后下跌了 3.4%